Clinical Trial: BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Ne

Brief Summary:

RATIONALE: BI 2536 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying the side effects and how well BI 2536 works in treating patients with recurrent or metastatic solid tumors.


Detailed Summary:

OBJECTIVES:

  • Investigate if BI 2536 demonstrates antitumor activity in the selected tumor types.
  • Further document its safety profile in the treated patient population.
  • Describe the plasma concentration time-course following administration of a single administration of BI 2536 in patients with different tumor types using an appropriate population pharmacokinetic model.

OUTLINE: This is a multicenter study.

Patients receive BI 2536 IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

Blood is collected periodically during study. Plasma samples are analyzed for pharmacokinetic studies by HPLC and tandem mass spectrometry.

After completion of study treatment, patients are followed every 3 months.


Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Current Primary Outcome: Confirmed objective response rate (complete and partial responses) as defined by RECIST

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Clinical benefit as assessed by RECIST
  • Duration of response
  • Overall progression-free survival
  • Overall survival
  • Safety as assessed by CTCAE version 3.0


Original Secondary Outcome: Same as current

Information By: European Organisation for Research and Treatment of Cancer - EORTC

Dates:
Date Received: September 5, 2007
Date Started: July 2007
Date Completion:
Last Updated: October 4, 2013
Last Verified: October 2013